Orserdu (Elacestrant)

Orserdu (elacestrant tablets) is an estrogen receptor antagonist used for the treatment of women who have gone through menopause and adult men with ER+, HER2-, ESR1-mutated advanced breast cancer or breast cancer that has progressed to other organs of the body (metastatic), and whose disease has progressed after one endocrine therapy.

Recommended Dosage: The recommended dosage of Orserdu tablets is 345 mg taken by mouth (orally) with food once daily until disease progression or in occurrence of unacceptable toxicity. Take Orserdu at about the common time each day. Take with meals to reduce vomiting and nausea. Swallow tablet(s) whole. Do not crush, chew, or split before swallowing the tablets. Avoid taking any broken, cracked, or damaged tablet.

If a dose of Orserdu is missed for beyond six hours or vomiting occurs, skip the particular dose and take the very next dose the following day at its regularly scheduled time. 

• Hypercholesterolemia (high amounts of cholesterol in the blood) and hypertriglyceridemia (high levels of fats/triglycerides in the blood) may occur in those taking Orserdu 345 mg pills. Monitor lipid profile before starting and periodically while taking this treatment.
  
• Based on findings in animals and its mechanism of action, this medication can cause fetal harm if administered to those who are pregnant. Females of reproductive potential should use effective contraception methods during treatment and for 7 days after the final dose.
  
• There is no finding on the existence of elacestrant in human milk, its impacts on milk production, or the breastfed baby. Due to the potential for severe adverse reactions in the breastfed baby, advise lactating women to not breastfeed during treatment with Elacestrant and for 7 days after the last dose.
  
• Avoid the use of Elacestrant pills in those with critical hepatic impairment (Child-Pugh C). Reduce the dose of this medicine in those with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is required for patients with mild hepatic impairment (Child-Pugh A).
  

What documents are required to import ORSERDU to India?

ORSERDU (elacestrant) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

ORSERDU (elacestrant tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Orserdu in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.
  

ORSERDU can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ORSERDU (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Orserdu 345 mg/86 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Orserdu®?

Elacestrant is a Generic Name for the trade name drug Orserdu®.

What is the Manufacturer’s Name of Orserdu®?

Orserdu® is manufactured by Stemline Therapeutics, Inc. (a subsidiary of Menarini Group).

Is Orserdu® approved by the FDA?

Yes, Orserdu® is approved by the FDA. Date of approval: January 27, 2023.

Where can I get Orserdu® at the best price in India?

To get the best Orserdu price in India, kindly connect with the Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Orserdu®, a medical prescription is required from a treating physician.

What is the dosage and form of Orserdu® supplied?

Orserdu® is supplied as Tablets: 345 mg and 86 mg for oral administration. 

What are the most common side effects of Orserdu®? 

The most common side effects of Orserdu® are headache, musculoskeletal pain, fatigue, vomiting, hot flush, nausea, decreased appetite, constipation, abdominal pain, diarrhea, and dyspepsia.

How much does Orserdu® cost in India?

The cost of Orserdu in India can vary. In order to procure this estrogen receptor antagonist legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Orserdu®?

Store the tablets of Orserdu® at a temperature of 20°C to 25°C (68°F to 77°F). Excursions permitted from 15-30°C (59-86°F).

Is it safe to buy Orserdu® online in India?

Yes, one can buy Orserdu online in India at the lowest price from the Indian Pharma Network (IPN) if the medicine Orserdu® is not (yet) registered or available in your country. We can help facilitate the supply of Orserdu® through legal channels.